| 초록 |
Cancer remains an incurable disease with a high global mortality rate. siRNAs have enormous potential as cancer therapies due to their high efficacy in cancer treatment. However, the siRNA therapeutics are rapidly degraded in vivo and have a limited ability to reach target cells. In this study, lipid nanoparticles (LNPs) packed with cancer cell death-inducing siRNA and immune cell extracellular vesicles (EVs) were hybridized for successful cancer treatment. The LNPs encapsulated with siRNA hybridized effectively to immune cell EVs. The hybrid LNPs were more successful at killing cancer cells than the control group. The expression of BCL2 was decreased, and cleaved caspase-3 was enhanced in hybrid LNP-treated cancer cells. In the mouse tumor model, hybrid LNPs effectively inhibited cancer growth. Taken together, this hybrid technology could be utilized as a new therapeutic platform to treat various diseases, including cancer. |
